Patents Assigned to TES Pharma S.r.l.
  • Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
    Patent number: 11254644
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: February 22, 2022
    Assignee: TES PHARMA S.R.L.
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
  • Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
    Patent number: 10513499
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: December 24, 2019
    Assignee: TES Pharma S.r.l.
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
  • Inhibitors of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase
    Patent number: 9708272
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 18, 2017
    Assignee: TES Pharma S.r.l.
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli